Researchers estimate the 20-year breast cancer-specific death rate for women diagnosed with ductal carcinoma in situ to be 3.3%, although the death rate is higher for women diagnosed before age 35 years and for black women, according to an article published online by JAMA Oncology (2015; doi:10.1001/jamaoncol.2015.2510).
Ductal carcinoma in situ breast (DCIS) cancer, which is also referred to as stage 0 breast cancer, accounts for about 20% of the breast cancers detected through mammography. Some women with DCIS experience a second breast cancer (DCIS or invasive) and a small proportion of patients with DCIS ultimately die of breast cancer. However, it is not clear what factors might predict mortality after a DCIS diagnosis. Women who develop an invasive breast cancer on the same side of the body have an increased risk of death but some women die without first receiving a diagnosis of local invasive disease.
Steven A. Narod, MD, FRCPC, of the Women’s College Hospital in Toronto, Ontario, Canada, and coauthors used the Surveillance, Epidemiology, and End Results (SEER) 18 registries database to study women diagnosed with DCIS from 1988 to 2011. The study ultimately included 108,196 women whose risk of dying of breast cancer was compared with that of women in the general population. The average age at diagnosis for women was nearly 54 years and the average duration of follow-up was 7.5 years.
Continue Reading
The authors estimated the 10-year breast cancer-specific death rate after DCIS diagnosis to be 1.1% and the rate at 20 years to be 3.3%. Compared with women in the general population, the risk of dying of breast cancer for a women who had a DCIS diagnosis was 1.8 times higher, according to the results.
At 20 years, the death rate was higher for women who received a diagnosis before age 35 years compared with older women (7.8% vs. 3.2%) and for black women compared with non-Hispanic white women (7% vs. 3%).
The authors noted the finding of “greatest clinical importance” was that preventing an ipsilateral (on the same side of the body) invasive recurrence did not prevent death from breast cancer. Among all patients, the risk of ipsilateral invasive recurrence at 20 years was 5.9% and the risk of contralateral (on the other side of the body) invasive recurrence was 6.2%.
For patients who had a lumpectomy, radiotherapy was associated with reduced the risk of developing an ipsilateral invasive recurrence (2.5% vs. 4.9%) but did not reduce breast cancer-specific death at 10 years (0.8% vs. 0.9%), the results indicate. Similarly, patients who had unilateral (single breast) mastectomy had a lower risk of ipsilateral invasive recurrence at 10 years than patients who had lumpectomy (1.3% vs. 3.3%) but had a higher breast cancer-specific death rate (1.3% vs. 0.8%).
A total of 517 women died of breast cancer following a DCIS diagnosis without experiencing an invasive cancer in the breast prior to death.
“Some cases of DCIS have an inherent potential for distant metastatic spread. It is therefore appropriate to consider these as de facto breast cancers and not as preinvasive markers predictive of a subsequent invasive cancer. The outcome of breast cancer mortality for DCIS patients is of importance in itself and potential treatments that affect mortality are deserving of study,” the study concluded.
